CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. (Q48098073)

8 February 2018

title

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. (English)

1 reference

8 February 2018

1 reference

Laure Elens

1

1 reference

8 February 2018

Annemieke Nieuweboer

2

1 reference

8 February 2018

Stephen J Clarke

3

1 reference

8 February 2018

Kellie A Charles

4

1 reference

8 February 2018

Anne-Joy de Graan

5

1 reference

8 February 2018

Vincent Haufroid

6

1 reference

8 February 2018

Ron H J Mathijssen

7

1 reference

8 February 2018

Ron H N van Schaik

8

1 reference

8 February 2018

publication date

1 January 2013

1 reference

8 February 2018

published in

Pharmacogenomics

1 reference

8 February 2018

volume

14

1 reference

8 February 2018

issue

2

1 reference

8 February 2018

page(s)

137-149

1 reference

8 February 2018

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Determining the best dose for the individual patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Factors influencing midazolam hydroxylation activity in human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

The erythromycin breath test for the prediction of drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Erythromycin breath test.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

The erythromycin breath test predicts the clearance of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Noninvasive tests of CYP3A enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

The erythromycin breath test as a predictor of cyclosporine blood levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Midazolam is metabolized by at least three different cytochrome P450 enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.202

21 January 2018

Identifiers

DOI

10.2217/PGS.12.202

1 reference

8 February 2018

PubMed ID

23327575

1 reference

8 February 2018